Chemoprevention of Mouse Colon Tumors with Difluoromethylornithine during and after Carcinogen Treatment

M. A. Tempero, K. Nishioka, Rowen K Zetterman, R. K. Zetterman

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

α-Difluoromethylornithine (DFMO) treatment has been shown to modify carcinogenesis in many experimental tumor models, including skin, breast, and colon. This study was designed to determine whether DFMO treatment can inhibit experimental mouse colon tumors after carcinogen treatment and whether an associated effect of DFMO on cell proliferation in colon mucosa occurs. Male CDi mice (40 per group) received dimethylhydrazine (30 mg/kg/week × 6 weeks, s.c.) and various schedules of DFMO, 1% in drinking waten Group A, none; Group B, following dimethylhydrazine treatment; Group C., during dimethylhydrazine treatment; and Group D, continuously throughout the study. Measurements of RBC polyamine levels showed that DFMO treatment ablated putrescine levels and confirmed that a systemic biological effect was achieved. Analysis of tumor data showed a significant inhibitory effect of DFMO treatment on colon tumor (adenomas and adenocarcinomas) incidence in Groups B (24%) and D (20%) compared to control Group A (52%, P < 0.05 A versus B, P < 0.02 A versus D) and on squamous cell carcinomas of the anus in all groups (P < 0.001 A versus B, P < 0.05 A versus C., A versus D). No consistent effect of DFMO treatment on cell proliferation in colon mucosa was identified. This study supports the hypothesis that DFMO treatment alters events in the postinitiation phases of mouse colon tumorigenesis.

Original languageEnglish (US)
Pages (from-to)5793-5797
Number of pages5
JournalCancer Research
Volume49
Issue number21
StatePublished - Nov 1 1989

Fingerprint

Eflornithine
Chemoprevention
Carcinogens
Colon
Dimethylhydrazines
Neoplasms
Therapeutics
Carcinogenesis
Mucous Membrane
Cell Proliferation
Putrescine
Polyamines
Anal Canal
Adenoma
Drinking
Squamous Cell Carcinoma
Appointments and Schedules
Adenocarcinoma
Breast
Theoretical Models

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chemoprevention of Mouse Colon Tumors with Difluoromethylornithine during and after Carcinogen Treatment. / Tempero, M. A.; Nishioka, K.; Zetterman, Rowen K; Zetterman, R. K.

In: Cancer Research, Vol. 49, No. 21, 01.11.1989, p. 5793-5797.

Research output: Contribution to journalArticle

Tempero, M. A. ; Nishioka, K. ; Zetterman, Rowen K ; Zetterman, R. K. / Chemoprevention of Mouse Colon Tumors with Difluoromethylornithine during and after Carcinogen Treatment. In: Cancer Research. 1989 ; Vol. 49, No. 21. pp. 5793-5797.
@article{dc67ad33cfe14ebe83d6f7e25464d31f,
title = "Chemoprevention of Mouse Colon Tumors with Difluoromethylornithine during and after Carcinogen Treatment",
abstract = "α-Difluoromethylornithine (DFMO) treatment has been shown to modify carcinogenesis in many experimental tumor models, including skin, breast, and colon. This study was designed to determine whether DFMO treatment can inhibit experimental mouse colon tumors after carcinogen treatment and whether an associated effect of DFMO on cell proliferation in colon mucosa occurs. Male CDi mice (40 per group) received dimethylhydrazine (30 mg/kg/week × 6 weeks, s.c.) and various schedules of DFMO, 1{\%} in drinking waten Group A, none; Group B, following dimethylhydrazine treatment; Group C., during dimethylhydrazine treatment; and Group D, continuously throughout the study. Measurements of RBC polyamine levels showed that DFMO treatment ablated putrescine levels and confirmed that a systemic biological effect was achieved. Analysis of tumor data showed a significant inhibitory effect of DFMO treatment on colon tumor (adenomas and adenocarcinomas) incidence in Groups B (24{\%}) and D (20{\%}) compared to control Group A (52{\%}, P < 0.05 A versus B, P < 0.02 A versus D) and on squamous cell carcinomas of the anus in all groups (P < 0.001 A versus B, P < 0.05 A versus C., A versus D). No consistent effect of DFMO treatment on cell proliferation in colon mucosa was identified. This study supports the hypothesis that DFMO treatment alters events in the postinitiation phases of mouse colon tumorigenesis.",
author = "Tempero, {M. A.} and K. Nishioka and Zetterman, {Rowen K} and Zetterman, {R. K.}",
year = "1989",
month = "11",
day = "1",
language = "English (US)",
volume = "49",
pages = "5793--5797",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Chemoprevention of Mouse Colon Tumors with Difluoromethylornithine during and after Carcinogen Treatment

AU - Tempero, M. A.

AU - Nishioka, K.

AU - Zetterman, Rowen K

AU - Zetterman, R. K.

PY - 1989/11/1

Y1 - 1989/11/1

N2 - α-Difluoromethylornithine (DFMO) treatment has been shown to modify carcinogenesis in many experimental tumor models, including skin, breast, and colon. This study was designed to determine whether DFMO treatment can inhibit experimental mouse colon tumors after carcinogen treatment and whether an associated effect of DFMO on cell proliferation in colon mucosa occurs. Male CDi mice (40 per group) received dimethylhydrazine (30 mg/kg/week × 6 weeks, s.c.) and various schedules of DFMO, 1% in drinking waten Group A, none; Group B, following dimethylhydrazine treatment; Group C., during dimethylhydrazine treatment; and Group D, continuously throughout the study. Measurements of RBC polyamine levels showed that DFMO treatment ablated putrescine levels and confirmed that a systemic biological effect was achieved. Analysis of tumor data showed a significant inhibitory effect of DFMO treatment on colon tumor (adenomas and adenocarcinomas) incidence in Groups B (24%) and D (20%) compared to control Group A (52%, P < 0.05 A versus B, P < 0.02 A versus D) and on squamous cell carcinomas of the anus in all groups (P < 0.001 A versus B, P < 0.05 A versus C., A versus D). No consistent effect of DFMO treatment on cell proliferation in colon mucosa was identified. This study supports the hypothesis that DFMO treatment alters events in the postinitiation phases of mouse colon tumorigenesis.

AB - α-Difluoromethylornithine (DFMO) treatment has been shown to modify carcinogenesis in many experimental tumor models, including skin, breast, and colon. This study was designed to determine whether DFMO treatment can inhibit experimental mouse colon tumors after carcinogen treatment and whether an associated effect of DFMO on cell proliferation in colon mucosa occurs. Male CDi mice (40 per group) received dimethylhydrazine (30 mg/kg/week × 6 weeks, s.c.) and various schedules of DFMO, 1% in drinking waten Group A, none; Group B, following dimethylhydrazine treatment; Group C., during dimethylhydrazine treatment; and Group D, continuously throughout the study. Measurements of RBC polyamine levels showed that DFMO treatment ablated putrescine levels and confirmed that a systemic biological effect was achieved. Analysis of tumor data showed a significant inhibitory effect of DFMO treatment on colon tumor (adenomas and adenocarcinomas) incidence in Groups B (24%) and D (20%) compared to control Group A (52%, P < 0.05 A versus B, P < 0.02 A versus D) and on squamous cell carcinomas of the anus in all groups (P < 0.001 A versus B, P < 0.05 A versus C., A versus D). No consistent effect of DFMO treatment on cell proliferation in colon mucosa was identified. This study supports the hypothesis that DFMO treatment alters events in the postinitiation phases of mouse colon tumorigenesis.

UR - http://www.scopus.com/inward/record.url?scp=0024430216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024430216&partnerID=8YFLogxK

M3 - Article

C2 - 2507137

AN - SCOPUS:0024430216

VL - 49

SP - 5793

EP - 5797

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 21

ER -